Restructuring Expenses

9 Months Ended

Sep. 30, 2020

Restructuring and Related Activities [Abstract]

RESTRUCTURING EXPENSES

In May 2020, we completed a restructuring to reduce the size of our organization in conjunction with the planned divestiture of Intrarosa and Vyleesi and expected declines in our revenue due to the COVID-19 pandemic. Approximately 110 employees were displaced through this workforce reduction. We recorded a one-time restructuring charge of $8.2 million primarily related to severance and related benefits on our condensed consolidated statement of operations during the second quarter of 2020 and expect the restructuring charges incurred to date under this program to be substantially paid in cash by the end of the second quarter of 2021.

In February 2019, we completed a restructuring to combine our women’s health and maternal health sales forces into one integrated sales team, which promotes Intrarosa, the Makena auto-injector and Vyleesi. Approximately 110 employees were displaced through this workforce reduction. We recorded one-time restructuring charges of $7.4 million primarily related to severance and related benefits on our condensed consolidated statement of operations during the first quarter of 2019. The remaining accrued restructuring charges incurred under this program will be paid in cash by the end of the first quarter of 2021.

The following table displays charges taken related to the restructuring during the nine months ended September 30, 2020 (in thousands):


2020 Restructuring charges:
Workforce reduction	$	8,090
Other	107
Total 2020 restructuring charges	$	8,197

The following table displays a rollforward of the changes to the accrued balances as of September 30, 2020 (in thousands):


	2019 Restructuring		2020 Restructuring		Total
Balance accrued at December 31, 2019	$	797	$	—	$	797
2020 Restructuring Charges	—		8,197		8,197
Workforce Reduction Payments	(626)		(6,665)		(7,291)
Other Payments	—		(107)		(107)
Balance accrued at September 30, 2020	$	171	$	1,425	$	1,596